Coffee reduces risk for hepatocellular carcinoma: An updated meta-analysis

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 11, 2013, Pages 1413-1421.e1

  Bravi, Francesca ^a,b   Bosetti, Cristina ^a   Tavani, Alessandra ^a   Gallus, Silvano ^a   La Vecchia, Carlo ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Caffeine; Chemoprevention; Epidemiology; Neoplasm

Indexed keywords

ALCOHOL CONSUMPTION; CANCER EPIDEMIOLOGY; CANCER RISK; CASE CONTROL STUDY; COFFEE; COHORT ANALYSIS; DISEASE ASSOCIATION; DRINKING BEHAVIOR; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER DISEASE; MEDICAL HISTORY; META ANALYSIS; REVIEW; RISK REDUCTION; SEX DIFFERENCE;

BMI; BODY MASS INDEX; CAFFEINE; CHEMOPREVENTION; CI; CONFIDENCE INTERVAL; D; DAY; EPIDEMIOLOGY; HBSAG; HBV; HCC; HCV; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATOCELLULAR CARCINOMA; NEOPLASM; ODDS RATIO; OR; RELATIVE RISK; RR; W; WEEK;

CARCINOMA, HEPATOCELLULAR; COFFEE; DIET; FEEDING BEHAVIOR; HUMANS; INCIDENCE; LIVER NEOPLASMS; RISK ASSESSMENT;

EID: 84885848163     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.04.039     Document Type: Review

References (53)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Bosetti C., Levi F., Boffetta P., et al. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008, 48:137-145.
3. Chuang S.C., La Vecchia C., Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett 2009, 286:9-14.
4. Franceschi S., Montella M., Polesel J., et al. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev 2006, 15:683-689.
5. La Vecchia C., Bosetti C. Oral contraceptives and neoplasms other than breast and female genital tract. Eur J Cancer Prev 2009, 18:407-411.
6. Trichopoulos D., Bamia C., Lagiou P., et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. JNatl Cancer Inst 2011, 103:1686-1695.
7. Bravi F., Bosetti C., Tavani A., et al. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology 2007, 46:430-435.
8. Hu G., Tuomilehto J., Pukkala E., et al. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology 2008, 48:129-136.
9. Inoue M., Kurahashi N., Iwasaki M., et al. Effect of coffee and green tea consumption on the risk of liver cancer: cohort analysis by hepatitis virus infection status. Cancer Epidemiol Biomarkers Prev 2009, 18:1746-1753.
10. Johnson S., Koh W.P., Wang R., et al. Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Cancer Causes Control 2011, 22:503-510.
11. Ohishi W., Fujiwara S., Cologne J.B., et al. Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2008, 17:846-854.
12. Kanazir M., Boricic I., Delic D., et al. Risk factors for hepatocellular carcinoma: a case-control study in Belgrade (Serbia). Tumori 2010, 96:911-917.
13. Leung W.W., Ho S.C., Chan H.L., et al. Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. JEpidemiol Community Health 2011, 65:556-558.
14. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
15. Kanwal F., White D. Systematic reviews and meta-analyses in Clinical Gastroenterology and Hepatology. Clin Gastroenterol Hepatol 2012, 10:1184-1186.
16. Ottawa Hospital Research Institute. The Newcastel-Ottawa Scale(NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: Accessed: March 13, 2013. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
17. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987, 9:1-30.
18. Greenland S., Longnecker M.P. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992, 135:1301-1309.
19. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
20. Gallus S., Bertuzzi M., Tavani A., et al. Does coffee protect against hepatocellular carcinoma?. Br J Cancer 2002, 87:956-959.
21. Gelatti U., Covolo L., Franceschini M., et al. Coffee consumption reduces the risk of hepatocellular carcinoma independently ofitsaetiology: a case-control study. JHepatol 2005, 42:528-534.
22. Inoue M., Yoshimi I., Sobue T., et al. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. JNatl Cancer Inst 2005, 97:293-300.
23. Montella M., Polesel J., La Vecchia C., et al. Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer 2007, 120:1555-1559.
24. Kurozawa Y., Ogimoto I., Shibata A., et al. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br JCancer 2005, 93:607-610.
25. Shimazu T., Tsubono Y., Kuriyama S., et al. Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer 2005, 116:150-154.
26. Ohfuji S., Fukushima W., Tanaka T., et al. Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: a case-control study. Hepatol Res 2006, 36:201-208.
27. Tanaka K., Hara M., Sakamoto T., et al. Inverse association between coffee drinking and the risk of hepatocellular carcinoma: a case-control study in Japan. Cancer Sci 2007, 98:214-218.
28. Thornton A., Lee P. Publication bias in meta-analysis: its causes and consequences. JClin Epidemiol 2000, 53:207-216.
29. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
30. Kuper H., Tzonou A., Kaklamani E., et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000, 85:498-502.
31. Wakai K., Kurozawa Y., Shibata A., et al. Liver cancer risk, coffee, and hepatitis C virus infection: a nested case-control study in Japan. Br J Cancer 2007, 97:426-428.
32. Yu S.Z., Huang X.E., Koide T., et al. Hepatitis B and C viruses infection, lifestyle and genetic polymorphisms as risk factors for hepatocellular carcinoma in Haimen, China. Jpn J Cancer Res 2002, 93:1287-1292.
33. Larsson S.C., Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 2007, 132:1740-1745.
34. Ferruzzi M.G. The influence of beverage composition on delivery of phenolic compounds from coffee and tea. Physiol Behav 2010, 100:33-41.
35. Tanaka T., Nishikawa A., Shima H., et al. Inhibitory effects of chlorogenic acid, reserpine, polyprenoic acid (E-5166), or coffee on hepatocarcinogenesis in rats and hamsters. Basic Life Sci 1990, 52:429-440.
36. Cavin C., Holzhauser D., Constable A., et al. The coffee-specific diterpenes cafestol and kahweol protect against aflatoxin B1-induced genotoxicity through a dual mechanism. Carcinogenesis 1998, 19:1369-1375.
37. Cavin C., Holzhaeuser D., Scharf G., et al. Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. Food Chem Toxicol 2002, 40:1155-1163.
38. Majer B.J., Hofer E., Cavin C., et al. Coffee diterpenes prevent the genotoxic effects of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and N-nitrosodimethylamine in a human derived liver cell line (HepG2). Food Chem Toxicol 2005, 43:433-441.
39. Tanaka K., Tokunaga S., Kono S., et al. Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol 1998, 27:438-443.
40. Ruhl C.E., Everhart J.E. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005, 128:24-32.
41. Huber W.W., Parzefall W. Modification of N-acetyltransferases andglutathione S-transferases by coffee components: possible relevance for cancer risk. Methods Enzymol 2005, 401:307-341.
42. Corrao G., Lepore A.R., Torchio P., et al. The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Provincial Group for the Study of Chronic Liver Disease. Eur J Epidemiol 1994, 10:657-664.
43. Corrao G., Zambon A., Bagnardi V., et al. Coffee, caffeine, and the risk of liver cirrhosis. Ann Epidemiol 2001, 11:458-465.
44. Gallus S., Tavani A., Negri E., et al. Does coffee protect against liver cirrhosis?. Ann Epidemiol 2002, 12:202-205.
45. Klatsky A.L., Armstrong M.A. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol 1992, 136:1248-1257.
46. Huxley R., Lee C.M., Barzi F., et al. Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. Arch Intern Med 2009, 169:2053-2063.
47. El-Serag H.B., Hampel H., Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006, 4:369-380.
48. Polesel J., Zucchetto A., Montella M., et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol 2009, 20:353-357.
49. D'Avanzo B., La Vecchia C., Katsouyanni K., et al. Reliability of information on cigarette smoking and beverage consumption provided by hospital controls. Epidemiology 1996, 7:312-315.
50. Ferraroni M., Tavani A., Decarli A., et al. Reproducibility and validity of coffee and tea consumption in Italy. Eur J Clin Nutr 2004, 58:674-680.
51. Jacobsen B.K., Bonaa K.H. The reproducibility of dietary data from a self-administered questionnaire. The Tromso Study. Int J Epidemiol 1990, 19:349-353.
52. Boffetta P., McLaughlin J.K., La Vecchia C., et al. False-positive results in cancer epidemiology: a plea for epistemological modesty. JNatl Cancer Inst 2008, 100:988-995.
53. La Vecchia C. Cancer and liver cancer prevention: is it a fact or just a potential?. Hepatology 2008, 48:7-9.